Literature DB >> 342394

Tumor inhibition by effector cells cultured from progressing sarcomas.

I Berczi, A H Sehon.   

Abstract

The effect of cytotoxic lymphoid cells emerging in primary cultures of an antigenic sarcoma of strain 13 guinea pigs was investigated on tumor growth in vivo. The growth of lethal tumor inocula was inhibited or the tumor cells were completely rejected in normal syngeneic recipients treated s.c. with low doses (5 X 10(5)) of effector cells which were mixed with the tumor cells. A higher dose (2.5 X 10(6)) of killer cells did not affect significantly tumor growth in normal recipients. Significant tumor inhibition was observed in X-irradiated recipients given high doses (2.2 X 10(6)) of effector cells locally although rejection did not occur with high frequency. Local treatment of X-irradiated recipients with low doses (5 X 10(5)) of effector cells did not influence tumor growth. Systemic treatment of normal or X-irradiated recipients with effector cells had little effect at any dose, although tumor inocula were occasionally rejected. Sonication of the cytotoxic effector cells prior to administration inhibited their tumor suppressing effect. Animals that rejected the first tumor inoculum were immune to a second lethal dose of sarcoma cells. It is indicated by the results that tumor rejection in vivo is not simply a matter of killer-target cell interaction, but rather a complex and poorly understood phenomenon.

Entities:  

Mesh:

Year:  1977        PMID: 342394     DOI: 10.3109/08820137709093471

Source DB:  PubMed          Journal:  Immunol Commun        ISSN: 0090-0877


  2 in total

1.  Tumour-derived lymphoid cells prevent tumour growth in Winn assays.

Authors:  R A Robins; G R Flannery; R W Baldwin
Journal:  Br J Cancer       Date:  1979-12       Impact factor: 7.640

2.  Cellular progression of neoplasia in the subcutis of mice after implantation of 3,4-benzpyrene.

Authors:  F R Westwood; E Longstaff; W H Butler
Journal:  Br J Cancer       Date:  1979-06       Impact factor: 7.640

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.